Weekly Newsletter (9/29) - GLP-1 Agonists and Cancer: Exploring New Health Benefits

Topic of the Month on ModernWeight: Redefining Weight Management Together: Let's Talk Stigma and Solutions

Head to the Social Hub to share your success story or learn about others.

AOMs in the News

This Week's Featured Post

What Impact Will GLP-1 Agonists Have on Cancer?

Link: Targeted Oncology

In this week's featured post, we explore the growing evidence suggesting that GLP-1 agonists, commonly used for obesity and diabetes management, could also reduce cancer risks. As these drugs are becoming more widely prescribed, understanding their long-term benefits, particularly regarding cancer prevention, is critical. The discussion around GLP-1 agonists has shifted beyond weight loss and metabolic health, leading to questions about their broader implications for other chronic conditions, such as cancer.

The article by Dr. John Burke highlights how GLP-1 agonists have been associated with a reduced risk in 10 out of 13 obesity-related cancers, including endometrial, pancreatic, and colon cancer. While the exact mechanisms are still under investigation, researchers believe that the weight loss and anti-inflammatory effects of GLP-1 drugs could reduce the overall cancer risk for patients with obesity. Additionally, these medications may offer an alternative to more invasive treatments, such as bariatric surgery, by reaching a broader range of patients.

Why It Matters: As obesity rates continue to rise in the U.S., understanding the long-term health impacts of weight loss drugs like GLP-1 agonists is critical. If future studies confirm these findings, we could see a paradigm shift in approaching cancer prevention alongside obesity treatment. This potential reduction in cancer risk is a promising development, especially considering the growing use of GLP-1s in patients without Type 2 diabetes.

Article 2: An Oral Weight Loss Pill Shows Promising Early Results

Link: Medical Xpress

Researchers at the European Association for the Study of Diabetes announced promising results from the Phase 1 trials of amycretin, an oral GLP-1 weight loss pill. Early trials demonstrated that amycretin can lead to a 13% reduction in body weight, with weight loss rates surpassing those of the injectable GLP-1 drugs. If approved, this pill could provide a more convenient option for patients uncomfortable with injections, offering a simpler approach to long-term obesity management.

Why It Matters: Amycretin’s development could change the landscape of weight management, providing patients with a pill-based option that could lower the barriers to adherence, especially for those with injection hesitancy. While further studies are required, amycretin’s efficacy in early trials suggests that we may soon see more convenient weight-loss solutions.

Article 3: GLP-1 Receptor Agonists for Weight Loss in Non-Diabetic Populations

Link: eClinicalMedicine

A new benefit-harm modeling study has evaluated the risks and benefits of GLP-1 receptor agonists for people with obesity but without diabetes. The study found that the benefits of achieving a 10% weight loss significantly outweigh the potential side effects, such as gastrointestinal discomfort or gallstones, over two years. The study also emphasizes that even a 5% weight loss can provide meaningful benefits for those less concerned about side effects.

Why It Matters: As GLP-1 medications become more popular for weight management, understanding their long-term effects in non-diabetic populations is vital. Personalized treatment based on individual goals and willingness to accept side effects could help optimize outcomes and reduce unnecessary risks.

Article 4: Considering Eating Disorders When Prescribing Weight Loss Drugs to Teens

Link: Medscape

With the rising popularity of GLP-1 medications like Ozempic, healthcare professionals are urging caution when prescribing these drugs to adolescents. Dr. Kim Dennis, a psychiatrist specializing in eating disorders, warns that GLP-1 drugs may exacerbate or trigger eating disorders in teens already struggling with body image issues. Recent studies show that up to 80% of teens undergoing obesity treatments exhibit symptoms of disordered eating, raising concerns about the broader mental health impacts of these medications.

Why It Matters: As weight loss medications become more accessible to younger populations, it is crucial to consider their potential effects on mental health. This article emphasizes the need for careful screening and ongoing mental health support for adolescents who are prescribed GLP-1 agonists for weight loss.

Article 5: How Pfizer’s 1990s Decision Affected Their Place in the GLP-1 Market

Link: Labiotech

In the 1990s, Pfizer opted out of an opportunity to further develop GLP-1 medications, a decision that has since left the company trailing behind in the highly lucrative weight loss drug market. Pfizer initially partnered with a small startup to explore GLP-1 therapies but ultimately pulled out due to concerns about the feasibility of injectable medications. Today, GLP-1 drugs are expected to surpass $100 billion in sales by 2030, and Pfizer’s absence from this market continues to be a significant missed opportunity.

Why It Matters: With GLP-1 medications dominating the weight loss and diabetes markets, Pfizer’s early exit from this area demonstrates how strategic missteps can have long-lasting consequences. Understanding the history of GLP-1 development underscores the importance of foresight and commitment to pharmaceutical innovation.

---

Expert Tweet of the Week

From @EricTopol

“The GLP-1 drugs are the most important drug class breakthrough in medical history. We're still learning how they have such broad impact, especially about their anti-inflammatory effects, systemically and in the brain”

Related Article: https://nature.com/articles/d41586-024-03074-1

A new feature @Nature, by @marilenharo

---

Our ModernWeight "Weekly Weight Management Insights" newsletter is designed to keep you informed and engaged with the latest in weight management and GLP-1 medications. Visit the Social Hub to join the conversation and connect with our community.

Want to receive this newsletter in your inbox weekly? Create a profile!